Xilio Therapeutics Inc — Financial Statements (NASDAQ:XLO) | MetaTrader

Open full chart

Nouvelles

Xilio Therapeutics obtient 35,8 millions d’euros grâce à l’exercice de bons de souscription

Xilio Therapeutics secures $35.8 million from warrant exercises

Le BPA de Xilio Development a manqué les attentes de 0,06$, le CA a surpassé les prévisions

Xilio Development earnings missed by $0.06, revenue topped estimates

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC - Slideshow (NASDAQ:XLO) 2025-11-11

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript

Xilio presents promising data for tumor-activated immunotherapies

Xilio reports 40% response rate in colorectal cancer treatment study

Xilio to present vilastobart phase 2 data at SITC annual meeting

Xilio Therapeutics va transférer sa cotation au Nasdaq Capital Market lundi